Indonesia Diabetes Drugs Market: Market Size & Forecast 2026

Indonesia's diabetes drugs market encompasses a range of therapeutic classes including insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and oral antidiabetic agents used to manage both Type 1 and Type 2 diabetes. The market has grown from an estimated USD 482.65 million in 2023, reflecting the country's position as one of the most diabetes-burdened nations in the world, with prevalence rates continuing to climb among its adult population. The Indonesian healthcare system has been expanding access to diabetes care through public insurance schemes and growing private sector investment in pharmaceutical infrastructure.

• •Indonesia ranked among the top countries globally for diabetes prevalence, with over 10 million adults estimated to be living with the condition
• •The market has shown steady growth from USD 482.65 million in 2023 toward projected values of USD 631.76 million by 2032 at a CAGR of 2.62%
• •Government universal health coverage programs have expanded patient access to essential diabetes medications across both public and private healthcare facilities

Rising diabetes prevalence is the primary catalyst for market expansion, fueled by Indonesia's rapid urbanization, changing dietary patterns toward processed foods, and increasing sedentary behavior among its growing middle class. Government initiatives, including national diabetes screening drives and awareness campaigns, are driving earlier diagnosis and treatment adoption rates across both urban and rural populations. Additionally, the increasing availability of newer drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors is expanding treatment options and driving higher spending per patient.

• •Indonesia's adult diabetes prevalence has risen significantly, with lifestyle-related risk factors including obesity, physical inactivity, and high carbohydrate consumption contributing to growing patient numbers
• •Government-led screening initiatives and public health campaigns are improving early detection rates, particularly in underserved regions
• •Growing healthcare expenditure, increasing insurance penetration, and rising patient awareness are expanding demand for both conventional and novel antidiabetic therapies

The Indonesia diabetes drugs market is segmented by drug class into insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and other oral antidiabetic agents, with insulin and oral medications currently dominating market share. By diabetes type, Type 2 diabetes accounts for the overwhelming majority of sales, while Type 1 represents a smaller but essential treatment segment. Regionally, Indonesia is one of the fastest-growing markets in the Asia-Pacific region, which as a whole is expanding at approximately 5.95% CAGR, supported by government screening programs across China, India, and Southeast Asian nations.

• •Insulin and oral antidiabetic drugs remain the largest segments by revenue, with GLP-1 receptor agonists experiencing rapid growth due to their efficacy and cardiovascular benefits
• •Type 2 diabetes dominates the market, representing over 90% of the diagnosed diabetes population in Indonesia
• •The Asia-Pacific human insulin therapeutics market alone is estimated at USD 7.67 billion in 2025, with Indonesia contributing a meaningful share of Southeast Asian demand

What are the recent trends and outlook?

The Indonesia diabetes drugs market is expected to maintain steady growth through 2034, supported by continued improvements in healthcare infrastructure, expanding insurance coverage, and the introduction of next-generation therapies with improved efficacy and safety profiles. GLP-1 receptor agonists and SGLT2 inhibitors are anticipated to capture increasing market share as clinical evidence supporting their cardiovascular and renal benefits drives physician prescribing preferences. Digital health integration, telemedicine expansion, and greater emphasis on preventive care are likely to reshape diabetes management approaches in Indonesia, potentially expanding the addressable patient population and supporting long-term market growth.

• •Next-generation GLP-1 receptor agonists and combination therapies are expected to drive premium market growth as they become more accessible to Indonesian patients
• •The broader global diabetes drugs market is projected to reach approximately USD 132 billion to USD 144 billion by 2034-2035, with Asia-Pacific continuing to represent one of the most dynamic regional markets
• •Strategic partnerships between multinational pharmaceutical companies and local distributors, combined with government health initiatives, are expected to accelerate market penetration and treatment adoption rates across Indonesia